The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Arynta
lisdexamfetamine dimesylate oral · LISDEXAMFETAMINE DIMESYLATE 10 mg/mL · Solution · Oral · Azurity Pharmaceuticals, Inc.
NDC 24338-0019-01 · 1 BOTTLE in 1 CARTON / 100 mL in 1 BOTTLE · NDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Regulatory
- Application
- NDA219847
- TE code
- —
- Approval date
- Jun 16, 2025
- Patents / exclusivity
- 3 patents, 0 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| patent | 11576878 | Aug 30, 2040 |
| patent | 12433859 | Apr 16, 2040 |
| patent | 12582620 | Apr 16, 2040 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of lisdexamfetamine dimesylate oral (Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Azurity Pharmaceuticals, Inc. | LISDEXAMFETAMINE DIMESYLATE 10 mg/mL | Jul 15, 2026 | Aug 31, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Arynta — NDC 24338-0019-01," retrieved September 3, 2026, https://drugdashboards.com/drug/24338001901.
Free to cite with attribution — see how the data is put together.